Dynavax to Present at CIBC Annual Biotechnology & Specialty Pharmaceutical Conference
BERKELEY, Calif., March 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the CIBC World Markets Annual Biotechnology & Specialty conference, April 4, 2006 at 9:30 a.m. Eastern, in New York. The webcast presentation may be accessed by visiting http://www.veracast.com/webcasts/cibcwm/biotech06/84103317.cfm .
The presentation may also be accessed by visiting the Dynavax website at http://www.Dynavax.com under the Investors section where it will also be archived for 30 days following the presentation.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, that has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV™, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacologic activity in a Phase 2a clinical trial.
SOURCE Dynavax Technologies Corporation
Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com
http://www.prnewswire.com